CGON Valuation

CG Oncology Inc

Add to Watchlist

Advanced Chart

26.820

+0.105(0.393%)1D

Overview
Forecast
Valuation
Earnings

CGON Relative Valuation

CGON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CGON is overvalued; if below, it's undervalued.

Historical Valuation

CG Oncology Inc (CGON) is now in the Fair zone, suggesting that its current forward PS ratio of 2269.91 is considered Fairly compared with the five-year average of -18.35. The fair price of CG Oncology Inc (CGON) is between 22.03 to 46.81 according to relative valuation methord.

Relative Value

Fair Zone

22.03-46.81

Current Price：26.82

Fair

-10.62

Trailing

Forward

-7.32

EV/EBITDA

CG Oncology Inc. (CGON) has a current EV/EBITDA of -7.32. The 5-year average EV/EBITDA is -14.39. The thresholds are as follows: Strongly Undervalued below -28.33, Undervalued between -28.33 and -21.36, Fairly Valued between -7.42 and -21.36, Overvalued between -7.42 and -0.45, and Strongly Overvalued above -0.45. The current Forward EV/EBITDA of -7.32 falls within the Overvalued range.

-6.43

EV/EBIT

CG Oncology Inc. (CGON) has a current EV/EBIT of -6.43. The 5-year average EV/EBIT is -14.45. The thresholds are as follows: Strongly Undervalued below -28.40, Undervalued between -28.40 and -21.43, Fairly Valued between -7.47 and -21.43, Overvalued between -7.47 and -0.50, and Strongly Overvalued above -0.50. The current Forward EV/EBIT of -6.43 falls within the Overvalued range.

2269.91

CG Oncology Inc. (CGON) has a current PS of 2269.91. The 5-year average PS is 3240.69. The thresholds are as follows: Strongly Undervalued below 618.77, Undervalued between 618.77 and 1929.73, Fairly Valued between 4551.65 and 1929.73, Overvalued between 4551.65 and 5862.61, and Strongly Overvalued above 5862.61. The current Forward PS of 2269.91 falls within the Historic Trend Line -Fairly Valued range.

-10.51

P/OCF

CG Oncology Inc. (CGON) has a current P/OCF of -10.51. The 5-year average P/OCF is -11.98. The thresholds are as follows: Strongly Undervalued below -33.49, Undervalued between -33.49 and -22.74, Fairly Valued between -1.22 and -22.74, Overvalued between -1.22 and 9.54, and Strongly Overvalued above 9.54. The current Forward P/OCF of -10.51 falls within the Historic Trend Line -Fairly Valued range.

-10.09

P/FCF

CG Oncology Inc. (CGON) has a current P/FCF of -10.09. The 5-year average P/FCF is -18.31. The thresholds are as follows: Strongly Undervalued below -29.62, Undervalued between -29.62 and -23.96, Fairly Valued between -12.66 and -23.96, Overvalued between -12.66 and -7.00, and Strongly Overvalued above -7.00. The current Forward P/FCF of -10.09 falls within the Overvalued range.

CG Oncology Inc (CGON) has a current Price-to-Book (P/B) ratio of 3.05. Compared to its 3-year average P/B ratio of 2.99 , the current P/B ratio is approximately 1.92% higher. Relative to its 5-year average P/B ratio of 2.99, the current P/B ratio is about 1.92% higher. CG Oncology Inc (CGON) has a Forward Free Cash Flow (FCF) yield of approximately -4.60%. Compared to its 3-year average FCF yield of -3.26%, the current FCF yield is approximately 41.28% lower. Relative to its 5-year average FCF yield of -3.26% , the current FCF yield is about 41.28% lower.

3.05

P/B

Median3y

2.99

Median5y

2.99

-4.60

FCF Yield

Median3y

-3.26

Median5y

-3.26

Competitors Valuation Multiple

The average P/S ratio for CGON's competitors is 1392.81, providing a benchmark for relative valuation. CG Oncology Inc Corp (CGON) exhibits a P/S ratio of 2269.91, which is 62.97% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Recursion Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Adaptive Biotechnologies Corp

Apogee Therapeutics Inc

Loss

2.17B

Performance Decomposition

Market capitalization of CGON decreased by 28.92% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -17.03K to -145.92K.

The secondary factor is the Revenue Growth, contributed -100.00%to the performance.

Overall, the performance of CGON in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-100.00%

111.00K → 0.00

Revenue Growth

756.90%

-17.03K → -145.92K

Margin Expansion

-685.82%

2.58 → -15.11

P/E Change

-28.92%